Table 3.
Contraindications, criteria for discontinuation of the infusion and place of administration and monitoring
| Contraindications | n/N (%) |
| Renal failure | 33/38 (87) |
| Electrolyte disorders | 19/38 (50) |
| Cardiovascular disease | 27/38 (71) |
| Respiratory distress | 2/38 (5) |
| Myasthenia gravis | 23/38 (61) |
| Delivery <30 min | 18/38 (47) |
| Digitalis interaction | 22/38 (58) |
| MgSO4 intolerance | 1/38 (3) |
| Stop the infusion if | |
| Oliguria <120 mL/4 h | 2/38 (5) |
| Oliguria <100 mL/4 h | 29/38 (76) |
| Hemodynamic instability | 31/38 (82) |
| Respiratory rate < 12/min | 6/38 (16) |
| Respiratory rate < 10/min | 28/38 (74) |
| Hyporeflexia | 35/38 (92) |
| Disorders of consciousness | 33/38 (87) |
| Other | 4/38 (1) |
| Place of administration | |
| Delivery room | 37/38 (97) |
| Recovery room | 19/38 (50) |
| Intensive care unit | 9/38 (24) |
| Obstetrics unit | 8/38 (21) |
Values are n/N (%)
Multiple answers were possible